9,151 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Centiva Capital LP

Centiva Capital LP bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 9,151 shares of the specialty pharmaceutical company's stock, valued at approximately $331,000.

A number of other large investors also recently made changes to their positions in the business. Summit Investment Advisors Inc. increased its holdings in shares of Supernus Pharmaceuticals by 7.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company's stock valued at $190,000 after purchasing an additional 369 shares during the period. Bank of Montreal Can increased its holdings in Supernus Pharmaceuticals by 6.6% in the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after buying an additional 473 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Supernus Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company's stock worth $800,000 after buying an additional 560 shares during the last quarter. HighTower Advisors LLC increased its holdings in Supernus Pharmaceuticals by 7.3% in the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after buying an additional 624 shares during the last quarter. Finally, Bridge City Capital LLC increased its holdings in Supernus Pharmaceuticals by 0.8% in the fourth quarter. Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company's stock worth $3,435,000 after buying an additional 761 shares during the last quarter.

Insider Activity

In other news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This represents a 10.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.80% of the stock is owned by company insiders.

Supernus Pharmaceuticals Trading Up 2.9%

Supernus Pharmaceuticals stock traded up $0.95 during trading hours on Friday, reaching $33.43. 548,988 shares of the company were exchanged, compared to its average volume of 489,907. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 31.24 and a beta of 0.74. The stock has a 50-day moving average of $31.88 and a 200 day moving average of $34.83.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SUPN shares. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.